Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Alzamend Neuro Inc
(NQ:
ALZN
)
1.040
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 5, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
1.040
Bid (Size)
1.000 (2)
Ask (Size)
1.110 (2)
Prev. Close
1.040
Today's Range
1.040 - 1.040
52wk Range
0.1132 - 2.032
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
12 Health Care Stocks Moving In Thursday's Pre-Market Session
November 30, 2023
Via
Benzinga
Why American Eagle Shares Are Trading Lower By Around 16%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
November 21, 2023
Shares of American Eagle Outfitters, Inc. (NYSE: AEO) declined during Tuesday’s session after the company reported third-quarter financial results. Net revenue rose 5% Y/Y to $1.30 billion, beating the...
Via
Benzinga
Performance
YTD
+79.31%
+79.31%
1 Month
-42.22%
-42.22%
3 Month
+270.11%
+270.11%
6 Month
+54.78%
+54.78%
1 Year
-7.14%
-7.14%
More News
Read More
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
November 21, 2023
Via
Benzinga
Why Symbotic Shares Are Trading Higher By Around 22%; Here Are 20 Stocks Moving Premarket
November 21, 2023
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
November 21, 2023
Via
InvestorPlace
12 Health Care Stocks Moving In Monday's After-Market Session
November 20, 2023
Via
Benzinga
Why ReNew Energy Global Shares Are Trading Higher By Around 14%? Here Are Other Stocks Moving In Monday's Mid-Day Session
November 20, 2023
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
November 20, 2023
Via
Benzinga
EXCLUSIVE: Alzamend Neuro Receives FDA Go-Ahead Letter For Mid-Stage Major Depressive Disorder Study
November 20, 2023
Via
Benzinga
Exposures
Product Safety
Alzamend Neuro Receives FDA “Study May Proceed” Notification for a Phase IIA Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, in Major Depressive Disorder Patients
November 20, 2023
From
Alzamend Neuro, Inc.
Via
Business Wire
EXCLUSIVE: Alzamend Neuro Seeks FDA Approval For Mid-Stage PTSD Study With Next‑Gen Lithium Therapeutic Drug Candidate
November 13, 2023
Via
Benzinga
Exposures
Product Safety
12 Health Care Stocks Moving In Wednesday's After-Market Session
November 08, 2023
Via
Benzinga
Alzamend Neuro Regains Compliance with Nasdaq’s Minimum Bid Price Requirement
November 16, 2023
From
Alzamend Neuro, Inc.
Via
Business Wire
Dow Surges Over 500 Points; Western Digital Announces Plan To Split Into Two Companies
October 30, 2023
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Alzamend Neuro Submits IND Application for a Phase IIA Clinical Trial in Post-Traumatic Stress Disorder Patients of Next‑Generation Lithium Therapeutic Drug Candidate AL001
November 13, 2023
From
Alzamend Neuro, Inc.
Via
Business Wire
Crude Oil Falls Over 3%; Miromatrix Medical Shares Spike Higher
October 30, 2023
Via
Benzinga
Topics
Stocks
Exposures
Fossil Fuels
US Equities
Why ON Semiconductor Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Monday's Mid-Day Session
October 30, 2023
Via
Benzinga
Why Alzamend Neuro (ALZN) Stock Is Nosediving Today
October 30, 2023
Via
Benzinga
Nasdaq Gains Over 1%; McDonald's Reports Upbeat Earnings
October 30, 2023
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Alzamend Neuro Announces Reverse Stock Split
October 30, 2023
From
Alzamend Neuro, Inc.
Via
Business Wire
EXCLUSIVE: Alzamend Neuro Submits IND For Phase IIA Trial Of Next-Gen Lithium Candidate In Major Depressive Disorder
October 23, 2023
Via
Benzinga
Exposures
Product Safety
EXCLUSIVE: Alzamend Neuro To Start Next-Gen Therapy Study For Bipolar Disorder
October 02, 2023
Via
Benzinga
Alzamend Neuro Submits IND Application for a Phase IIA Clinical Trial in Major Depressive Disorder Patients of its Next‑Generation Lithium Therapeutic Drug Candidate AL001
October 23, 2023
From
Alzamend Neuro, Inc.
Via
Business Wire
NetSol Technologies And 2 Other Stocks Under $2 Insiders Are Buying
September 27, 2023
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Alzamend Neuro Receives FDA “Study May Proceed” Notification for a Phase IIA Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder Patients
October 02, 2023
From
Alzamend Neuro, Inc.
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.